Filing Flows › Biodesix (BDSX) › Q1 2026
Biodesix (BDSX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
Biodesix (BDSX) reported revenue of $25.6M for the first quarter 2026 (Q1 2026), +42% from a year earlier and -11% from the quarter before. Operating margin was -24.3%, net loss $7.8M (30.5% of revenue).
Biodesix, Q1 2026: revenue $25.6M (+42% year over year), operating margin -24.3%, net loss $7.8M, operating cash flow −$10.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.6M | -11% | +42% |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$7.8M | — | — |
| Operating cash flow | −$10.2M | -1407% | — |
What changed
Revenue was $25.6M in Q1 2026, up 42% year over year and down 11% from the previous quarter. Diagnostic Tests was the largest line at 87% of revenue. Diagnostic Tests added $6.0M year over year (up 37%), 79% of the total change.
Operating costs exceeded revenue by $6.2M, an operating margin of -24.3%. Total costs grew 17% against revenue growth of 42%. The fastest-growing cost line was SG&A (+19%). The quarter ended with a net loss of $7.8M, wider than the previous quarter's $4.0M loss.
Operating cash flow was −$10.2M. Non-cash charges added back $1.4M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $81K exceeded it, leaving free cash flow of −$10.2M.
Questions
What was Biodesix's revenue in the first quarter 2026?
Biodesix (BDSX) reported revenue of $25.6M for the first quarter 2026 (Q1 2026), +42% from a year earlier and -11% from the quarter before.
Was Biodesix profitable in the first quarter 2026?
Operating loss was $6.2M (-24.3% of revenue) and net loss $7.8M.
Source: Biodesix 10-Q on SEC EDGAR.